GlassScriptPhysician profile
Kevin Soong
NPI 1528589017
$4,825.56
in general payments reported to CMS, 2019-2025
22 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $291 · 2021: $725 · 2022: $1,170 · 2023: $506 · 2024: $620 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.70 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,654.62 | 2021-2025 | |
| Alcon Vision LLC | $774.75 | 2019-2025 | Precision7, Precision 1, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $401.25 | 2019-2021 | |
| Allergan, INC. | $342.65 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $282.05 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Abbvie INC. | $218.46 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Maculogix, INC. | $201.17 | 2019 | |
| Shire North American Group INC | $178.35 | 2019 | |
| Carl Zeiss Meditec, INC. | $176.35 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $168.02 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $86.00 | 2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $72.84 | 2022-2023 | Acuvue |
| Oyster Point Pharma, INC. | $52.76 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $39.00 | 2021 | |
| Rxsight INC | $25.67 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $24.97 | 2020 | |
| Sun Pharmaceutical Industries INC. | $24.90 | 2020 | |
| Aerie Pharmaceuticals, INC. | $24.81 | 2020 | |
| Visioneering Technologies, INC. | $21.56 | 2021 | |
| Coopervision INC. | $21.18 | 2024 | Clariti Contact Lens |
| Dompe US, INC. | $17.33 | 2021 | |
| Horizon Therapeutics Plc | $16.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Soong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.